CN Patent

CN117794545A — 骨髓纤维化的治疗中的生物标志物和患者选择

Assigned to GlaxoSmithKline LLC · Expires 2024-03-29 · 2y expired

What this patent protects

通过选择患者特异性治疗方法，可以改善骨髓纤维化患者的输血非依赖性和总体存活。患者的基线铁蛋白水平可以用作选择一线治疗的生物标志物。治疗期间患者的铁蛋白水平可以告知关于终止治疗或改变治疗以维持输血依赖性和/或将患者从输血需要的或输血依赖的转变至输血非依赖的决定。

USPTO Abstract

通过选择患者特异性治疗方法，可以改善骨髓纤维化患者的输血非依赖性和总体存活。患者的基线铁蛋白水平可以用作选择一线治疗的生物标志物。治疗期间患者的铁蛋白水平可以告知关于终止治疗或改变治疗以维持输血依赖性和/或将患者从输血需要的或输血依赖的转变至输血非依赖的决定。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN117794545A
Jurisdiction: CN
Classification: —
Expires: 2024-03-29
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.